by Tony Akiwumi | Nov 1, 2025 | Pharma / Market Access
For decades, regulators and payers have operated in parallel worlds. Regulators judged safety and efficacy. Payers judged value and affordability. Between them sat a gap large enough to stall innovation. In today’s complex environment, that separation no longer works....
by Tony Akiwumi | Nov 1, 2025 | Pharma / Market Access
Healthcare systems face huge pressure from aging, chronic illness, and high costs. Yet much of the industry’s innovation still targets treatment rather than prevention. The economic logic is flawed but familiar: prevention saves systems money, not companies. As a...
by Tony Akiwumi | Oct 30, 2025 | Pharma / Market Access
Corporate purpose statements are everywhere — printed on annual reports, displayed in office lobbies, and recited at town halls. “We transform patients’ lives.” “We advance health for all.” Yet the real test of purpose comes not in words but in trade-offs. When...
by Tony Akiwumi | Oct 30, 2025 | Pharma / Market Access
When health technology assessment (HTA) systems were created, they were designed for a different era. The model assumed large, randomised trials, broad populations, and incremental innovation. Today, personalised medicine is rewriting that script. We are moving from...
by Tony Akiwumi | Oct 30, 2025 | Pharma / Market Access
When I first managed a market access team, I thought leadership meant having the answers. It didn’t take long to learn that it meant asking the right questions. The pace of science, regulation, and digital transformation means no single person can master it all. The...
